Greater Providence MRI Ltd. Partnership v. Medical Imaging Network of Southern New England, Inc.

32 F. Supp. 2d 491, 1998 U.S. Dist. LEXIS 19442, 1998 WL 879068
CourtDistrict Court, D. Rhode Island
DecidedDecember 10, 1998
DocketC.A. 98-0027L
StatusPublished
Cited by9 cases

This text of 32 F. Supp. 2d 491 (Greater Providence MRI Ltd. Partnership v. Medical Imaging Network of Southern New England, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Rhode Island primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Greater Providence MRI Ltd. Partnership v. Medical Imaging Network of Southern New England, Inc., 32 F. Supp. 2d 491, 1998 U.S. Dist. LEXIS 19442, 1998 WL 879068 (D.R.I. 1998).

Opinion

MEMORANDUM AND ORDER

LAGUEUX, Chief Judge.

Magnetic resonance imaging (“MRI”) allows doctors to peer inside a patient’s body and diagnose maladies invisible to x-rays and standard examination. In Rhode Island, the only companies currently licensed to provide those services are Greater Providence MRI Limited Partnership (“plaintiff’) and Rhode Island Magnetic Resonance Imaging Network, Inc. (“RIMRIN”).

Plaintiff alleges antitrust violations against United Healthcare of New England, Inc. (“United”), a health maintenance organization, and Medical Imaging Network of Southern New England, Inc. (“Medical Imaging”), a company that provides MRI services in Rhode Island by subcontracting to RIMRIN. United and Medical Imaging (“defendants”) have an exclusive contract by which United only reimburses its customers for MRIs performed by Medical Imaging and its subcontractor RIMRIN. Plaintiff alleges that the contract has the effect of reducing competition and facilitating a monopoly by Medical Imaging and RIMRIN in Rhode Island.

Specifically, plaintiff filed a five-count Amended Complaint: Count I for exclusive dealing under Section 3 of the Clayton Act, 15 U.S.C. § 14; Couht II for restraint of trade under Section 1 of the Sherman Act, 15 U.S.C. § 1; Count III for exclusive dealing under Section 6 of the Rhode Island Antitrust Act, R.I.Gen.Laws § 6-36-6; Count IV for restraint of trade under Section 4 of the Rhode Island Antitrust Act, R.I.Gen.Laws § 6-36-4; and Count V for exclusive dealing under Section 6 of the Rhode Island Antitrust Act.

Plaintiff defines the relevant geographic market as greater Providence, including Providence, Kent and Bristol counties. Plaintiff defines two separate and independent business markets involving the use of MRI machines: 1) a product component consisting of the scans recorded on film (“MRI Scans”) and 2) a service component consisting of the diagnostic interpretation of the *493 film (“Diagnostic Services”). Plaintiff alleges that three insurance providers, United, Blue Cross & Blue Shield and Medicare/Medicaid, account for more than 85% of Rhode Island’s insured patient base.

Plaintiff alleges that physicians determine the need for MRI Scans and refer their patients to an MRI provider. Therefore, it is critical for an MRI provider to be able to market its products and services to physicians. Those physicians, plaintiff alleges, want diagnostic facilities to handle all three major insurance providers so physicians need not worry whether a specific patient will be reimbursed for using a specific MRI provider. Because MRI Scans are expensive, patients “virtually never” go outside their insurance plans.

Each defendant has filed (1) a motion to dismiss all counts on the ground that no antitrust violation (state or federal) has been alleged, and (2) a motion to dismiss or grant partial summary judgment on Counts III, IV and V, the state law claims, on the ground that the exclusive contract here is exempted under state antitrust law because it was approved by two state regulatory agencies.

In considering the first motions to dismiss, this Court must take all well-pled allegations as true. This analogizes to a doctor who can only examine by hand a patient with a possible malignancy buried beneath bone and flesh. The doctor must assume the worst because she cannot see inside the patient’s body. In the future, a summary judgment motion may, like an MRI scan, provide this Court with relevant facts from which to draw inferences and settle whether defendants’ contract is a malady that must be cured. And, of course, there always lurks the possibility of the law’s invasive equivalent of an operation — a trial to root out any malignancy through the details of testimony and evidence.

However, at this stage, it is inappropriate to dismiss plaintiffs allegations. As outlined below, plaintiff has alleged facts that, if proven, may constitute a federal or state antitrust violation. United’s counsel is correct that the claims are remarkable, but the law is clear that this Court cannot consider the likelihood of plaintiffs success at this juncture. Therefore, each defendant’s motion to dismiss all counts is denied.

As to each defendant’s motion to dismiss or grant partial summary judgment on Counts III, IV and V, this Court enjoys less guidance. Defendants argue that state antitrust law does not reach this case because the statute exempts contracts approved by a state regulatory agency. Plaintiff offers a conflicting reading of the statute, and this Court finds no compelling or even persuasive precedent in Rhode Island law. These counts are significant but secondary to the federal claims, and as such, it is appropriate to allow Rhode Island to articulate its own law. Therefore, the Court will not make brevis disposition and may certify a question to the Rhode Island Supreme Court, if that becomes necessary, when the facts are sufficiently developed.

DISCUSSION

I. Legal Standard for Motion to Dismiss

In ruling on a motion to dismiss, the Court construes the complaint in the light most favorable to the plaintiff, taking all well-pleaded allegations as true and giving the plaintiff the benefit of all reasonable inferences. See Negron-Gaztambide v. Hernandez-Torres, 35 F.3d 25, 27 (1st Cir.1994), cert. denied, 513 U.S. 1149, 115 S.Ct. 1098, 130 L.Ed.2d 1066 (1995). Dismissal under Rule 12(b)(6) is appropriate only if “it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim which would entitle him to relief.” Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct. 99, 102, 2 L.Ed.2d 80 (1957).

II. Defendants’ Motions To Dismiss All Counts

The tests for exclusive dealing are essentially the same under Section 1 of the Sherman Act and Section 3 of the Clayton Act. See Mozart Co. v. Mercedes-Benz of North America, Inc., 833 F.2d 1342, 1352 (9th Cir.1987). The substantive test under Rhode Island antitrust laws is comparable. See R.I.Gen.Laws § 6—36—2(b). See also ERI Max Entertainment, Inc. v. Streisand, 690 A.2d 1351, 1353 n. 1 (R.I.1997).

*494 This case does not present any allegations, such as secondary boycott, that would require a per se test. See U.S. Healthcare, Inc. v. Healthsource, Inc.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Reynolds v. Coyne-Fague
D. Rhode Island, 2021
Leo Brynes Trust v. Brynes
D. Rhode Island, 2021
Brownell v. Coyne-Fague
D. Rhode Island, 2020
Riley v. Antonelli
D. Rhode Island, 2020
Henry v. Sheffield
749 F. Supp. 2d 3 (D. Rhode Island, 2010)
Pascale Service Corp. v. International Truck & Engine Corp.
558 F. Supp. 2d 217 (D. Rhode Island, 2008)
Morey v. Rhode Island
359 F. Supp. 2d 71 (D. Rhode Island, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
32 F. Supp. 2d 491, 1998 U.S. Dist. LEXIS 19442, 1998 WL 879068, Counsel Stack Legal Research, https://law.counselstack.com/opinion/greater-providence-mri-ltd-partnership-v-medical-imaging-network-of-rid-1998.